Posts tagged as:
Amgen received unanimous FDA approval for Dmab. This means their drug PROLIA may be commercially available for the treatment of osteoporosis. The stock is actually lower in very negative tape this morning, and the at-the-money August straddle is much lower with the result now known.
The August 60 calls are down by 37 [...]
{ 0 comments }
Late yesterday, Amgen (AMGN) announced the success of a Phase-3 trial; in response, the shares are up almost 15% in early trading. The options action has been similarly frantic in the first 15 minutes. More than 50,000 contracts have crossed the tape as option traders place their bets for the next move.
My [...]
{ 0 comments }
